Archives

The ADC was setup in 2004 by including all patients who come to the Alzheimer Center for diagnostic work up and who consent to give all data, collected as part of the routine diagnostic work up, for research. The aim is and was to facilitate research into new and existing biomarkers in the broadest sense, to establish diagnostic, prognostic and theragnostic values and further insight into the pathogenesis of neurodegenerative dementias. The data are collected on a weekly basis and consist of baseline data and annual follow up data. Since it is conception it has grown into one of the largest clinical databases in the dementia field. More info on setup, characteristics and data collection can be found in van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, van Egmond E, Scheltens P.

Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313-27. doi: 10.3233/JAD-132306. PubMed PMID: 24614907.

Last Update 21/09/2017

Alberta’s Tomorrow Project (ATP) is a longitudinal study tracking the health of 55,000 adults aged 35-69 years in this western Canadian province. ATP was launched in 2000 as a prospective cohort research platform to study the relationship between environmental, lifestyle, and genetic factors and the incidence of cancer and chronic diseases.

In 2008, ATP joined a nation-wide research platform called the Canadian Partnership for Tomorrow Project (CPTP) representing more than 300,000 participants from five provincial cohorts: Alberta, British Columbia, Ontario, Quebec and the Atlantic provinces (Prince Edward Island, New Brunswick, Newfoundland and Labrador, and Nova Scotia). Together, the consortium of five regional studies provides greater statistical power for research, as well as opportunities to examine geographical trends in health and wellbeing across Canada’s vast landscape.

The information contained herein is specific to the ATP cohort.

Last Update 21/09/2017

The EADC-PET project (EAPP, The European Alzheimer’s Disease Consortium PET project) is a spontaneous multicentric study (ProtocolDraftSep2008; ProtocolDraftFeb2009) involving at the moment five Centres in four Countries (CENTRES), belonging to the EADC consortium. It was launched during the EADC meeting in Amsterdam, during fall 2007, by Flavio Nobili (Genoa) who is the Principal Investigator.

The project aims at sharing FDG-PET, MRI, neuropsychological, genetic, EEG and clinical information of patients with amnestic Mild Cognitive Impairment (aMCI) and matched healthy controls. Information is uploaded in a safe FTP facility on the server of University of Genoa. Username and password have been provided to all participants. Use of data is regulated by a ‘Confidentiality Disclosure Agreement’ that can be downloaded from this web site (Confidential_Disclosure_Agreement). The Centres propose original studies by sending a formal proposal to all participants who can agree or disagree, or propose modifications/suggestions to the original proposal.

The objective is to follow-up aMCI patients with clinical and neuropsychological examinations to pick up conversion to Alzheimer’s dementia or to other forms of dementia. FDG-PET can be analyzed by means of several post-processing strategies to highlight glucose metabolic information and to identify the characteristics of what is today called ‘prodromal’ AD.

Last Update 21/09/2017

The EVA study was a 9-year longitudinal study with 6 waves of follow-ups. During the two-year period 1991-1993 (EVA0), 1389 men and women born between 1922 and 1932 were recruited.

The aim is to investigate vascular ageing, decline in brain and cognitive function and associated factors with a longitudinal follow-up study. The secondary objective is to determine to role of biological factors linked with oxidative stress and brain ageing.
Inclusion criteria Subjects from both genders born between 1922 and 1932 (59 to 71 years old at enrolment), included in electoral registers in Nantes, can speak French and living in Nantes.

Last Update 21/09/2017

The aim of GS: SFHS is to establish a large, family-based intensively-phenotyped cohort recruited from the general population across Scotland, as a resource for studying the genetics of health areas of current and projected public health importance. It aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.

Baseline data was collected at a single clinic visit. Longitudinal data is available by linkage to NHS medical records. Some participants are being invited to new clinic visits in 2015-17. This profile also includes scanning information from the Stratifying Resilience and Depression Longitudinally (STRADL) study to which approximately 1500 GS participants are being invited for scanning.

Last Update 21/09/2017

The PROTECT Study will gather data and support innovative research to improve our understanding of the ageing brain and why people develop dementia.

We know that certain factors such as exercise, smoking and blood pressure affect our risk of dementia, and there is increasing evidence that our genes also play a role.

Participants in PROTECT will provide information about themselves and complete online assessments to measure their abilities such as memory and reasoning. By repeating these assessments each year we will monitor how they change over the study. Participants will also provide a sample of their DNA through a simple at-home kit. PROTECT participants will also have the opportunity to take part in innovative studies to answer crucial questions such as:

  • How do key measures, such as memory, language and reasoning change over time as we age
  • How do our lifestyle choices, including our exercise habits and diet affect our risk of dementia
  • What role do genetics play in the ageing brain? How do they affect how our brain functions and what is their influence on development of dementia?
  • What are the early signs of dementia and how can they be distinguished from normal ageing
  • What approaches can be delivered online to influence the ageing process and the development of dementia?

Last Update 21/09/2017

The Older Australian Twins Study is a longitudinal, multi-centre study that investigates healthy brain ageing in older twins (65+ years). OATS commenced in New South Wales in January 2007, in Queensland in December 2007, and in Victoria in February 2008. Since the OATS study started we have followed our twin volunteers up every two years to check on their psychological and physical health. Participants undergo rigorous medical and cognitive function tests, with many participants’ also providing bloods samples and having a magnetic resonance imaging (MRI) scan of their brain. In 2015 we finished our 4-year follow ups. OATS assessed 623 participants at baseline, 450 at the 2-year follow up, and 389 completed their 4-year follow-up.

Last Update 21/09/2017

The Puerto Rican Elderly: Health Conditions (PREHCO) study investigates issues affecting the elderly (individuals over 60 years of age) population in Puerto Rico: health status, housing arrangements, functional status, transfers, labor history, migration, income, childhood characteristics, health insurance, use of health services, marital history, mistreat, sexuality, etc. It is an island-wide, longitudinal sample survey of target individuals and their spouses with two waves of data collection: 2002-2003 and 2006-2007.

In the first phase of the PREHCO project, 4,291 elderly persons 60 years or older and 1,442 spouses were interviewed (1,042 of the latter being 60 years or older). A second wave of the project (2006-2007) converted PREHCO in a longitudinal study. In the second wave, those same participants were asked to do a follow-up survey, in which 3,891 target interviews and 1,260 spouse interviews were completed. The deceased and institutionalized participants were also interviewed using a proxy.

Last Update 21/09/2017

The rpAD study is a longitudinal study, which recruits patients from the entire federal territory. In addition, patients from the Clinical Dementia Centre are recruited at the Neurological and Psychiatric Clinic of the University Medical Center of G’ttingen, with these usually classical clinical forms being internal controls. The aim of the study is to characterize the biological factors and parameters that define the disease progression in AD.

After the patient is informed and consent is given, the inclusion examination is carried out. It includes a detailed history and anamnesis as well as a physical examination, which includes an in-depth examination of the neurological status. A neuropsychological test for cognitive testing is performed using the CERAD-plus test battery. Furthermore, the GDS score is obtained, which allows an assessment of the severity of the cognitive deficits by means of a 7-stage classification. The ADL score is used to assess the activities of daily life (Lawton and Brody 1969).

Six months after the initial examination, a telephone follow-up is carried out. Further investigations are carried out on an annual basis and correspond to the initial examination.

Last Update 21/09/2017

The Rhineland Study is a prospective cohort study, which began in March 2016. It will include up to 30,000 participants from Bonn and asses their physical and mental health over their lifespan. The study is scheduled to run for decades and participants will be re-examined every 3-4 years.

As neurodegenerative diseases and their pathologies develop over a long time before first symptoms start to show, the Rhineland Study will include men and women aged 30 years and above regardless of their health status.
The main aims of the study are:

1. To investigate modifiable and non-modifiable causes of neurodegenerative and neuropsychiatric diseases
2. To find biomarkers/(multimodal) biomarker profiles to identify individuals at risk for neurodegenerative or neuropsychiatric disease, who might benefit from preventive interventions
3. To investigate (patho)physiology over the adult life course, with specific emphasis on brain-related outcomes.

Last Update 21/09/2017